CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CPT1A (ImmuneEditome ID:1374)

1. Gene summary of enriched editing regions for CPT1A

check button Gene summary
Gene informationGene symbol

CPT1A

Gene ID

1374

GeneSynonymsCPT1|CPT1-L|L-CPT1
GeneCytomap

11q13.3

GeneTypeprotein-coding
GeneDescriptioncarnitine O-palmitoyltransferase 1, liver isoform|CPT I|CPTI-L|carnitine palmitoyltransferase 1A (liver)|carnitine palmitoyltransferase I, liver
GeneModificationdate20230517
UniprotIDP50416;A0A024R5F4;H3BMD2;H3BP22;H3BUV7;H3BUJ0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr11:68755426-68756115:-ENST00000265641.8ENSG00000110090.11CPT1AUTR3(T)n,AluSq,AluYchr11:68755426-68756115:-.alignment
chr11:68758053-68758940:-ENST00000265641.8ENSG00000110090.11CPT1AintronicAluJb,AluSzchr11:68758053-68758940:-.alignment
chr11:68758053-68758940:-ENST00000376618.5ENSG00000110090.11CPT1AintronicAluJb,AluSzchr11:68758053-68758940:-.alignment
chr11:68758053-68758940:-ENST00000539743.4ENSG00000110090.11CPT1AintronicAluJb,AluSzchr11:68758053-68758940:-.alignment
chr11:68758053-68758940:-ENST00000540367.4ENSG00000110090.11CPT1AintronicAluJb,AluSzchr11:68758053-68758940:-.alignment
chr11:68765960-68768634:-ENST00000537756.2ENSG00000110090.11CPT1AncRNA_intronicCharlie4a,AluY,AluSx1,AluSq,MER58B,AluSz6,AluJb,MER4C,AluSzchr11:68765960-68768634:-.alignment
chr11:68784385-68784576:-ENST00000265641.8ENSG00000110090.11CPT1AintronicAluSzchr11:68784385-68784576:-.alignment
chr11:68784385-68784576:-ENST00000376618.5ENSG00000110090.11CPT1AintronicAluSzchr11:68784385-68784576:-.alignment
chr11:68784385-68784576:-ENST00000539743.4ENSG00000110090.11CPT1AintronicAluSzchr11:68784385-68784576:-.alignment
chr11:68784385-68784576:-ENST00000540367.4ENSG00000110090.11CPT1AintronicAluSzchr11:68784385-68784576:-.alignment
chr11:68789496-68794706:-ENST00000265641.8ENSG00000110090.11CPT1AexonicAluY,AluSx1,AluSq,L1ME1,MLT1C,AluSq2,AluSx,MER94,L1M,AluJbchr11:68789496-68794706:-.alignment
chr11:68789496-68794706:-ENST00000376618.5ENSG00000110090.11CPT1AexonicAluY,AluSx1,AluSq,L1ME1,MLT1C,AluSq2,AluSx,MER94,L1M,AluJbchr11:68789496-68794706:-.alignment
chr11:68789496-68794706:-ENST00000538994.1ENSG00000110090.11CPT1AexonicAluY,AluSx1,AluSq,L1ME1,MLT1C,AluSq2,AluSx,MER94,L1M,AluJbchr11:68789496-68794706:-.alignment
chr11:68789496-68794706:-ENST00000539743.4ENSG00000110090.11CPT1AexonicAluY,AluSx1,AluSq,L1ME1,MLT1C,AluSq2,AluSx,MER94,L1M,AluJbchr11:68789496-68794706:-.alignment
chr11:68789496-68794706:-ENST00000540367.4ENSG00000110090.11CPT1AexonicAluY,AluSx1,AluSq,L1ME1,MLT1C,AluSq2,AluSx,MER94,L1M,AluJbchr11:68789496-68794706:-.alignment
chr11:68806051-68806902:-ENST00000265641.8ENSG00000110090.11CPT1AintronicAluJb,AluSqchr11:68806051-68806902:-.alignment
chr11:68806051-68806902:-ENST00000376618.5ENSG00000110090.11CPT1AintronicAluJb,AluSqchr11:68806051-68806902:-.alignment
chr11:68806051-68806902:-ENST00000539743.4ENSG00000110090.11CPT1AintronicAluJb,AluSqchr11:68806051-68806902:-.alignment
chr11:68806051-68806902:-ENST00000540367.4ENSG00000110090.11CPT1AintronicAluJb,AluSqchr11:68806051-68806902:-.alignment
chr11:68838686-68838868:-ENST00000265641.8ENSG00000110090.11CPT1AintronicAluJrchr11:68838686-68838868:-.alignment
chr11:68838686-68838868:-ENST00000376618.5ENSG00000110090.11CPT1AintronicAluJrchr11:68838686-68838868:-.alignment
chr11:68838686-68838868:-ENST00000561996.1ENSG00000110090.11CPT1AintronicAluJrchr11:68838686-68838868:-.alignment
chr11:68838686-68838868:-ENST00000569129.4ENSG00000110090.11CPT1AintronicAluJrchr11:68838686-68838868:-.alignment


Top

2. Tumor-specific enriched editing regions for CPT1A


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr11:68755426-68756115:-BRCAEER2.7519e-06image
ENSG00000110090.11,CPT1ABRCAEAG2.6566e-04image
chr11:68755426-68756115:-COADEER2.3643e-12image
ENSG00000110090.11,CPT1ACOADEAG5.4790e-12image
chr11:68755426-68756115:-HNSCEER2.0291e-04image
ENSG00000110090.11,CPT1AHNSCEAG5.0667e-04image
chr11:68755426-68756115:-KICHEER9.9919e-03image
ENSG00000110090.11,CPT1AKICHEAG9.8939e-03image
chr11:68755426-68756115:-KIRCEER2.9205e-02image
ENSG00000110090.11,CPT1AKIRCEAG3.7138e-02image
chr11:68755426-68756115:-KIRPEER3.7488e-03image
ENSG00000110090.11,CPT1AKIRPEAG2.3307e-03image
chr11:68755426-68756115:-LUADEER1.0792e-08image
ENSG00000110090.11,CPT1ALUADEAG4.4740e-07image
chr11:68755426-68756115:-LUSCEER1.9394e-08image
ENSG00000110090.11,CPT1ALUSCEAG2.4875e-08image
chr11:68755426-68756115:-STADEER2.7472e-02image
chr11:68755426-68756115:-THCAEER4.7773e-03image
ENSG00000110090.11,CPT1ATHCAEAG7.8055e-03image
chr11:68755426-68756115:-UCECEER2.0728e-08image
ENSG00000110090.11,CPT1AUCECEAG5.7767e-08image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000110090.11,CPT1AKIRPCliEAG7.2714e-042.9252e-020.1550image
ENSG00000110090.11,CPT1ATGCTPathEAG5.9510e-035.5850e-030.3110image
chr11:68755426-68756115:-TGCTPathEER1.0568e-021.5671e-020.2728image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for CPT1A


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:68755426-68756115:-COADEERENSG00000237758,BANF1P30.20331.9560e-021.5054e-130.4296imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr11:68755426-68756115:-COADEERENSG00000266019,MIR36090.15382.4877e-026.6749e-180.4925imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr11:68755426-68756115:-COADEERENSG00000218596,RP11-2J18.10.15693.5436e-021.6795e-150.4594imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr11:68755426-68756115:-LAMLEERENSG00000180667,YOD10.33663.6940e-024.7222e-070.4000imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_HEME_METABOLISM
chr11:68755426-68756115:-UVMEERENSG00000172456,FGGY0.38062.3198e-023.9362e-040.4177imageNNNAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
chr11:68765960-68768634:-LAMLEERENSG00000234093,RPS15AP11-0.43461.1924e-021.5430e-06-0.4240imageNNNANK_cells_activatedGSVA_HALLMARK_APICAL_JUNCTION
chr11:68765960-68768634:-LAMLEERENSG00000112473,SLC39A70.39522.7399e-021.1487e-070.4630imageNNNAEosinophilsGSVA_HALLMARK_GLYCOLYSIS

More results



Top

4. Enriched editing regions and immune related splicing for CPT1A


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:68755426-68756115:-
COADEERMEXENSG00000080189.10chr2046355103:46355241:46355801:46355813:46356397:46356637:46357622:463577010.23981.5813e-021.6674e-140.4468imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr11:68755426-68756115:-
COADEERMEXENSG00000111361.8chr12123622635:123622761:123624786:123624923:123626424:123627156:123630168:1236302850.30005.4596e-042.7474e-160.4714imageNNNANeutrophilsGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
ENSG00000110090.11,CPT1A
KIRCEAGESENSG00000102781.9chr1330240958:30241086:30255446:30255615:30280062:30280223-0.13024.6737e-027.7565e-30-0.6136imageNACIN1;ADAR;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RNF219;SF3A3;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YWHAG;ZNF184NAPlasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000110090.11,CPT1A
KIRCEAGIRENSG00000167978.12chr162770910:2771049:2771120:27714120.18841.9486e-021.7269e-160.4038imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RBM5;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_TGF_BETA_SIGNALING
chr11:68755426-68756115:-
PCPGEERMEXENSG00000215021.4chr126967891:6968021:6968410:6968542:6968584:6968595:6969497:6969577-0.40652.6917e-041.2214e-07-0.4023imageNNNANK_cells_restingGSVA_HALLMARK_HEME_METABOLISM
chr11:68755426-68756115:-
STADEERIRENSG00000184007.13chr131937986:31938059:31938118:31938186-0.21852.6946e-034.4708e-16-0.4055imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr11:68755426-68756115:-
STADEERA5ENSG00000065183.11chr1117933287:117933389:117929774:117929795:117929774:1179299240.14406.3408e-031.2350e-110.4027imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr11:68755426-68756115:-
UVMEERA3ENSG00000110721.7chr1168065785:68065894:68064524:68064614:68064524:680646310.36764.4060e-021.1954e-040.4497imageNNNAGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

5. Enriched editing regions and immune infiltration for CPT1A


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr11:68755426-68756115:-ACCEERT_cells_gamma_delta4.3748e-040.4037image
ENSG00000110090.11,CPT1AACCEAGT_cells_gamma_delta3.9333e-040.4066image
chr11:68755426-68756115:-BLCAEERDendritic_cells_resting3.0400e-02-0.1121image
ENSG00000110090.11,CPT1ABLCAEAGDendritic_cells_resting3.2285e-02-0.1106image
chr11:68755426-68756115:-BRCAEEREosinophils2.0349e-02-0.0712image
ENSG00000110090.11,CPT1ABRCAEAGMacrophages_M19.8391e-03-0.0789image
chr11:68755426-68756115:-CESCEERMacrophages_M11.8788e-020.1365image
ENSG00000110090.11,CPT1ACESCEAGMacrophages_M13.9195e-020.1199image
chr11:68755426-68756115:-COADEERNeutrophils1.9414e-030.1878image
ENSG00000110090.11,CPT1ACOADEAGMast_cells_activated6.0860e-030.1662image
chr11:68755426-68756115:-ESCAEEREosinophils1.3073e-020.1965image
chr11:68765960-68768634:-ESCAEERT_cells_CD82.4782e-02-0.4160image
ENSG00000110090.11,CPT1AESCAEAGEosinophils6.0182e-030.2163image
chr11:68755426-68756115:-GBMEERNK_cells_resting3.3094e-020.1681image
ENSG00000110090.11,CPT1AGBMEAGNK_cells_resting2.3077e-020.1790image
chr11:68755426-68756115:-HNSCEERMacrophages_M11.3925e-030.1459image
ENSG00000110090.11,CPT1AHNSCEAGMacrophages_M14.2941e-030.1305image
chr11:68755426-68756115:-KICHEERDendritic_cells_activated2.2908e-030.3718image
ENSG00000110090.11,CPT1AKICHEAGDendritic_cells_activated2.0180e-030.3761image
ENSG00000110090.11,CPT1AKIRCEAGPlasma_cells3.5318e-030.1485image
chr11:68755426-68756115:-KIRPEERT_cells_CD82.2679e-02-0.1352image
ENSG00000110090.11,CPT1AKIRPEAGT_cells_CD4_memory_activated3.8486e-030.1707image
chr11:68755426-68756115:-LAMLEERB_cells_naive1.7203e-030.2556image
chr11:68765960-68768634:-LAMLEERDendritic_cells_resting6.2884e-030.2491image
chr11:68789496-68794706:-LAMLEERT_cells_CD4_naive1.8564e-02-0.2316image
ENSG00000110090.11,CPT1ALAMLEAGMacrophages_M14.3132e-030.2326image
chr11:68755426-68756115:-LGGEERT_cells_CD4_naive5.0782e-050.1776image
ENSG00000110090.11,CPT1ALGGEAGT_cells_CD4_naive3.2163e-050.1819image
chr11:68755426-68756115:-LIHCEERMonocytes1.6492e-020.1244image
ENSG00000110090.11,CPT1ALIHCEAGMonocytes4.3110e-030.1479image
chr11:68755426-68756115:-LUADEERT_cells_gamma_delta4.5447e-060.2042image
ENSG00000110090.11,CPT1ALUADEAGT_cells_gamma_delta1.7604e-050.1909image
chr11:68755426-68756115:-LUSCEERNK_cells_activated2.0302e-020.1054image
ENSG00000110090.11,CPT1ALUSCEAGNK_cells_activated1.6821e-020.1085image
chr11:68755426-68756115:-MESOEERT_cells_CD4_memory_resting1.5218e-02-0.2689image
ENSG00000110090.11,CPT1AMESOEAGT_cells_CD4_naive1.7064e-020.2644image
chr11:68755426-68756115:-OVEERT_cells_gamma_delta1.3752e-040.2217image
ENSG00000110090.11,CPT1AOVEAGT_cells_gamma_delta5.1681e-050.2350image
chr11:68755426-68756115:-PAADEERB_cells_naive7.3660e-04-0.2521image
ENSG00000110090.11,CPT1APAADEAGB_cells_naive1.2220e-03-0.2418image
chr11:68755426-68756115:-PCPGEEREosinophils1.1000e-020.1999image
ENSG00000110090.11,CPT1APCPGEAGEosinophils2.7732e-020.1730image
chr11:68755426-68756115:-PRADEERT_cells_gamma_delta2.0388e-020.1041image
ENSG00000110090.11,CPT1APRADEAGT_cells_gamma_delta4.9392e-020.0882image
chr11:68755426-68756115:-SARCEERT_cells_regulatory_(Tregs)2.5888e-02-0.1415image
ENSG00000110090.11,CPT1ASARCEAGT_cells_regulatory_(Tregs)2.0487e-02-0.1471image
chr11:68755426-68756115:-STADEEREosinophils2.0438e-050.2195image
chr11:68789496-68794706:-STADEERT_cells_gamma_delta1.3830e-050.6874image
ENSG00000110090.11,CPT1ASTADEAGEosinophils6.1303e-060.2323image
chr11:68755426-68756115:-TGCTEERDendritic_cells_resting8.3102e-030.2148image
ENSG00000110090.11,CPT1ATGCTEAGDendritic_cells_resting2.1311e-030.2489image
chr11:68755426-68756115:-THCAEERT_cells_regulatory_(Tregs)9.5999e-060.1975image
ENSG00000110090.11,CPT1ATHCAEAGT_cells_regulatory_(Tregs)5.1822e-050.1809image
chr11:68755426-68756115:-THYMEERMacrophages_M02.0125e-020.2156image
ENSG00000110090.11,CPT1ATHYMEAGMacrophages_M02.9583e-020.2021image
chr11:68755426-68756115:-UCECEERDendritic_cells_resting3.0250e-02-0.1677image
ENSG00000110090.11,CPT1AUCECEAGDendritic_cells_resting3.6522e-02-0.1620image
chr11:68755426-68756115:-UCSEERT_cells_CD4_memory_resting6.4244e-030.3664image
ENSG00000110090.11,CPT1AUCSEAGT_cells_CD4_memory_resting1.7747e-020.3215image
chr11:68755426-68756115:-UVMEERPlasma_cells2.2784e-020.2759image
ENSG00000110090.11,CPT1AUVMEAGPlasma_cells2.2784e-020.2759image


Top

6. Enriched editing regions and immune gene sets for CPT1A


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000110090.11,CPT1ASTADEAG3.0031e-030.15372.4414e-020.11683.3673e-030.15192.6412e-040.1883image
chr11:68755426-68756115:-STADEER2.6827e-040.18843.5239e-030.15135.6624e-040.17842.0975e-040.1916image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000110090.11,CPT1AACCGSVA_HALLMARK_MYOGENESISEAG5.9233e-04-0.3951image
chr11:68755426-68756115:-ACCGSVA_HALLMARK_MYOGENESISEER5.5631e-04-0.3969image
chr11:68755426-68756115:-BLCAGSVA_HALLMARK_HEME_METABOLISMEER2.3821e-02-0.1170image
ENSG00000110090.11,CPT1ABLCAGSVA_HALLMARK_UV_RESPONSE_DNEAG7.1230e-03-0.1388image
chr11:68755426-68756115:-BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.2433e-050.1271image
ENSG00000110090.11,CPT1ABRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.8472e-040.1141image
chr11:68755426-68756115:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.1778e-040.2133image
ENSG00000110090.11,CPT1ACESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8069e-040.2160image
ENSG00000110090.11,CPT1ACOADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG8.7905e-04-0.2009image
chr11:68755426-68756115:-COADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.1549e-03-0.1967image
ENSG00000110090.11,CPT1AESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.7053e-020.1884image
chr11:68765960-68768634:-ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.1660e-030.5291image
chr11:68755426-68756115:-ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER6.2530e-030.2160image
chr11:68755426-68756115:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.9670e-060.2056image
ENSG00000110090.11,CPT1AHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0503e-040.1767image
ENSG00000110090.11,CPT1AKICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.4347e-02-0.2629image
chr11:68755426-68756115:-KICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.4524e-02-0.2627image
ENSG00000110090.11,CPT1AKIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.4128e-02-0.1251image
chr11:68755426-68756115:-KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2982e-02-0.1268image
ENSG00000110090.11,CPT1AKIRPGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG6.1274e-03-0.1620image
chr11:68755426-68756115:-KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.0419e-02-0.1375image
chr11:68755426-68756115:-LAMLGSVA_HALLMARK_UV_RESPONSE_DNEER4.6650e-040.2841image
chr11:68765960-68768634:-LAMLGSVA_HALLMARK_GLYCOLYSISEER5.4341e-040.3124image
ENSG00000110090.11,CPT1ALAMLGSVA_HALLMARK_UV_RESPONSE_DNEAG8.7236e-040.2699image
ENSG00000110090.11,CPT1ALGGGSVA_HALLMARK_COAGULATIONEAG1.6063e-07-0.2282image
chr11:68755426-68756115:-LGGGSVA_HALLMARK_COAGULATIONEER6.5678e-08-0.2353image
ENSG00000110090.11,CPT1ALIHCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG3.8318e-020.1076image
chr11:68755426-68756115:-LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.9850e-020.1128image
ENSG00000110090.11,CPT1ALUADGSVA_HALLMARK_PEROXISOMEEAG6.2868e-030.1222image
chr11:68755426-68756115:-LUADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8091e-030.1398image
ENSG00000110090.11,CPT1ALUSCGSVA_HALLMARK_SPERMATOGENESISEAG9.3590e-05-0.1764image
chr11:68755426-68756115:-LUSCGSVA_HALLMARK_SPERMATOGENESISEER1.9382e-04-0.1685image
ENSG00000110090.11,CPT1AOVGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.9761e-02-0.1366image
chr11:68755426-68756115:-PAADGSVA_HALLMARK_MYC_TARGETS_V2EER7.8792e-04-0.2508image
ENSG00000110090.11,CPT1APAADGSVA_HALLMARK_MYC_TARGETS_V2EAG2.8914e-04-0.2701image
ENSG00000110090.11,CPT1APCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG8.9650e-040.2585image
chr11:68755426-68756115:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER6.7319e-040.2652image
ENSG00000110090.11,CPT1APRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.3209e-04-0.1603image
chr11:68755426-68756115:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.6158e-04-0.1686image
ENSG00000110090.11,CPT1ASARCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.2793e-02-0.1579image
chr11:68755426-68756115:-SARCGSVA_HALLMARK_G2M_CHECKPOINTEER5.8430e-030.1746image
chr11:68755426-68756115:-SKCMGSVA_HALLMARK_UV_RESPONSE_DNEER1.7889e-02-0.1163image
ENSG00000110090.11,CPT1ASKCMGSVA_HALLMARK_UV_RESPONSE_DNEAG1.8552e-02-0.1157image
chr11:68755426-68756115:-STADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2184e-070.2708image
chr11:68765960-68768634:-STADGSVA_HALLMARK_MYC_TARGETS_V1EER1.7634e-020.3603image
ENSG00000110090.11,CPT1ASTADGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.1477e-060.2293image
chr11:68755426-68756115:-TGCTGSVA_HALLMARK_E2F_TARGETSEER1.4028e-020.2002image
ENSG00000110090.11,CPT1ATGCTGSVA_HALLMARK_ADIPOGENESISEAG2.2361e-030.2478image
chr11:68755426-68756115:-THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.2894e-050.1891image
ENSG00000110090.11,CPT1ATHCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG4.4755e-050.1824image
ENSG00000110090.11,CPT1AUCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5609e-04-0.2885image
chr11:68755426-68756115:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER6.6515e-04-0.2608image


Top

7. Enriched editing regions and drugs for CPT1A


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000110090.11,CPT1AACCBMS.509744EAG2.3129e-030.3536image
chr11:68755426-68756115:-ACCBMS.509744EER2.8721e-030.3464image
chr11:68755426-68756115:-BLCAMidostaurinEER4.6877e-030.1461image
ENSG00000110090.11,CPT1ABLCAMidostaurinEAG5.5573e-030.1429image
chr11:68755426-68756115:-BRCAGSK269962AEER1.0455e-02-0.0787image
ENSG00000110090.11,CPT1ABRCAGSK269962AEAG5.5714e-04-0.1057image
chr11:68755426-68756115:-CESCCGP.60474EER1.0790e-02-0.1480image
ENSG00000110090.11,CPT1ACESCCGP.60474EAG2.1111e-03-0.1780image
chr11:68755426-68756115:-COADABT.263EER7.6090e-03-0.1621image
ENSG00000110090.11,CPT1ACOADGW843682XEAG6.0324e-030.1664image
ENSG00000110090.11,CPT1ADLBCAZ628EAG3.3319e-02-0.3253image
ENSG00000110090.11,CPT1AESCAABT.888EAG3.6663e-020.1654image
chr11:68765960-68768634:-ESCABIRB.0796EER3.8235e-020.3867image
chr11:68755426-68756115:-ESCAAZD6244EER1.0562e-02-0.2023image
chr11:68755426-68756115:-GBMCytarabineEER7.2296e-030.2110image
ENSG00000110090.11,CPT1AGBMCytarabineEAG1.3768e-020.1938image
ENSG00000110090.11,CPT1AHNSCDoxorubicinEAG3.6897e-03-0.1327image
chr11:68755426-68756115:-HNSCAZD.2281EER2.5792e-03-0.1377image
ENSG00000110090.11,CPT1AKICHAG.014699EAG1.0501e-02-0.3154image
chr11:68755426-68756115:-KICHAG.014699EER1.0268e-02-0.3163image
ENSG00000110090.11,CPT1AKIRCAZD6244EAG1.8331e-12-0.3493image
chr11:68755426-68756115:-KIRCAZD6244EER1.5083e-03-0.1616image
ENSG00000110090.11,CPT1AKIRPAS601245EAG3.1627e-030.1743image
chr11:68765960-68768634:-LAMLBexaroteneEER4.2058e-04-0.3182image
chr11:68789496-68794706:-LAMLAICAREER6.7834e-030.2652image
chr11:68755426-68756115:-LAMLMetforminEER6.6146e-060.3609image
ENSG00000110090.11,CPT1ALAMLMetforminEAG2.4716e-040.2960image
ENSG00000110090.11,CPT1ALGGKU.55933EAG3.3194e-050.1818image
chr11:68755426-68756115:-LGGKU.55933EER5.0787e-050.1777image
ENSG00000110090.11,CPT1ALIHCCamptothecinEAG4.8948e-020.1023image
chr11:68755426-68756115:-LIHCKIN001.135EER1.6804e-02-0.1241image
ENSG00000110090.11,CPT1ALUADKIN001.135EAG9.4133e-040.1476image
chr11:68755426-68756115:-LUADKIN001.135EER1.2355e-030.1447image
chr11:68755426-68756115:-LUSCBosutinibEER8.1452e-05-0.1779image
ENSG00000110090.11,CPT1ALUSCBosutinibEAG2.4137e-05-0.1905image
ENSG00000110090.11,CPT1AMESOLapatinibEAG5.8210e-030.3038image
chr11:68755426-68756115:-MESOLapatinibEER7.8048e-030.2936image
chr11:68755426-68756115:-OVCyclopamineEER2.1499e-04-0.2157image
ENSG00000110090.11,CPT1AOVCyclopamineEAG2.0908e-04-0.2161image
chr11:68755426-68756115:-PAADBleomycinEER4.8895e-040.2601image
ENSG00000110090.11,CPT1APAADBleomycinEAG2.9266e-040.2698image
chr11:68755426-68756115:-PCPGDasatinibEER1.9753e-020.1871image
ENSG00000110090.11,CPT1APCPGDasatinibEAG2.6646e-020.1775image
ENSG00000110090.11,CPT1APRADBMS.536924EAG1.1044e-04-0.1731image
chr11:68755426-68756115:-PRADBMS.536924EER2.2901e-04-0.1652image
chr11:68755426-68756115:-READBX.795EER6.5767e-03-0.2770image
ENSG00000110090.11,CPT1AREADBX.795EAG6.2547e-03-0.2786image
chr11:68755426-68756115:-SARCBosutinibEER7.0796e-030.1706image
ENSG00000110090.11,CPT1ASARCKIN001.135EAG5.8686e-03-0.1745image
chr11:68755426-68756115:-SKCMFH535EER7.9771e-03-0.1302image
ENSG00000110090.11,CPT1ASKCMFH535EAG3.4912e-03-0.1432image
chr11:68765960-68768634:-STADBI.D1870EER1.5805e-02-0.3660image
chr11:68789496-68794706:-STADBortezomibEER3.3527e-02-0.3768image
chr11:68755426-68756115:-STADEpothilone.BEER4.7799e-04-0.1807image
ENSG00000110090.11,CPT1ASTADDocetaxelEAG1.5128e-03-0.1641image
ENSG00000110090.11,CPT1ATGCTGDC0941EAG2.6884e-030.2434image
chr11:68755426-68756115:-TGCTGDC0941EER7.9767e-030.2159image
chr11:68755426-68756115:-THCAKU.55933EER1.5840e-07-0.2332image
ENSG00000110090.11,CPT1ATHCAKU.55933EAG9.2954e-07-0.2186image
chr11:68755426-68756115:-THYMCyclopamineEER1.3056e-020.2299image
ENSG00000110090.11,CPT1ATHYMCyclopamineEAG4.5513e-020.1861image
ENSG00000110090.11,CPT1AUCECAICAREAG7.8813e-060.3381image
chr11:68755426-68756115:-UCECAICAREER9.3957e-050.2976image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr11:68755426-68756115:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68755426-68756115:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68755426-68756115:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000376618.5P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000376618.5P50416DB01016GlyburideSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000376618.5P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000539743.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000539743.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000539743.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000540367.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000540367.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68758053-68758940:-ENST00000540367.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000376618.5P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000376618.5P50416DB01016GlyburideSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000376618.5P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000539743.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000539743.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000539743.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000540367.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000540367.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68784385-68784576:-ENST00000540367.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000376618.5P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000376618.5P50416DB01016GlyburideSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000376618.5P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000539743.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000539743.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000539743.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000540367.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000540367.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68789496-68794706:-ENST00000540367.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000376618.5P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000376618.5P50416DB01016GlyburideSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000376618.5P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000539743.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000539743.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000539743.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000540367.4P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000540367.4P50416DB01016GlyburideSmallMoleculeDrug
chr11:68806051-68806902:-ENST00000540367.4P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000265641.8P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000265641.8P50416DB01016GlyburideSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000265641.8P50416DB01074PerhexilineSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000376618.5P50416DB00583LevocarnitineSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000376618.5P50416DB01016GlyburideSmallMoleculeDrug
chr11:68838686-68838868:-ENST00000376618.5P50416DB01074PerhexilineSmallMoleculeDrug